{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:12:23Z","timestamp":1791911543190,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oral Maxillofac Surg"],"DOI":"10.1007\/s10006-026-01587-9","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:04:34Z","timestamp":1782457474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Timing of surgery after neoadjuvant immunochemotherapy in head and neck squamous cell carcinoma: Current evidence, surgical implications, and a research agenda"],"prefix":"10.1007","volume":"30","author":[{"given":"Abdullah","family":"Qahtan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Sayadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslah","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"1587_CR1","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B et al (2020) Neoadjuvant and adjuvant Pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res 26:5140\u20135152","journal-title":"Clin Cancer Res"},{"key":"1587_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33080-8","volume":"13","author":"WT Ju","year":"2022","unstructured":"Ju WT, Xia RH, Zhu DW, Dou SJ, Zhu GP, Dong MJ et al (2022) A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun 13:5378","journal-title":"Nat Commun"},{"key":"1587_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hed.26935","volume":"44","author":"N Amin","year":"2022","unstructured":"Amin N, Maroun CA, El Asmar M, Alkhatib HH, Guller M, Herberg ME et al (2022) Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: systematic review. Head Neck 44:562\u2013571","journal-title":"Head Neck"},{"key":"1587_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","volume":"147","author":"R Masarwy","year":"2021","unstructured":"Masarwy R, Kampel L, Horowitz G, Gutfeld O, Muhanna N (2021) Neoadjuvant PD-1\/PD-L1 inhibitors for resectable head and neck cancer: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 147:871\u2013878","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"1587_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1097\/JS9.0000000000000489","volume":"109","author":"Y Huang","year":"2023","unstructured":"Huang Y, Sun J, Li J, Zhu D, Dong M, Dou S et al (2023) Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate trial). Int J Surg 109:2220\u20132227","journal-title":"Int J Surg"},{"key":"1587_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101930","author":"H-M Liu","year":"2025","unstructured":"Liu H-M, Xiong X-P, Yu Z-L, Shao Z, Chen G-L, Liu Y-T et al (2025) Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: randomized, two-arm, phase 2 trial. Cell Rep Med. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101930","journal-title":"Cell Rep Med"},{"key":"1587_CR7","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1038\/s41467-025-59004-w","volume":"16","author":"Z Xiang","year":"2025","unstructured":"Xiang Z, Wei X, Zhang Z, Tang Y, Chen L, Tan C et al (2025) Efficacy, safety and single-cell analysis of neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma: a phase II trial. Nat Commun 16:3968","journal-title":"Nat Commun"},{"key":"1587_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1742883","volume":"16","author":"H Seng","year":"2026","unstructured":"Seng H, Fan Y, Zhao R, Liu Y, Meng J, Wang Z et al (2026) Optimal timing of surgery in head and neck squamous cell carcinoma after neoadjuvant immunochemotherapy. Front Oncol 16:1742883","journal-title":"Front Oncol"},{"key":"1587_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002568","volume":"9","author":"RL Ferris","year":"2021","unstructured":"Ferris RL, Spanos WC, Leidner R, Gon\u00e7alves A, Martens UM, Kyi C et al (2021) Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer 9:e002568","journal-title":"J Immunother Cancer"},{"key":"1587_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46444-z","volume":"15","author":"D Wu","year":"2024","unstructured":"Wu D, Li Y, Xu P, Fang Q, Cao F, Lin H et al (2024) Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nat Commun 15:2177","journal-title":"Nat Commun"},{"key":"1587_CR11","doi-asserted-by":"publisher","first-page":"104742","DOI":"10.1016\/j.critrevonc.2025.104742","volume":"212","author":"CM Pedroso","year":"2025","unstructured":"Pedroso CM, de Pauli PM, Normando AGC, Chaves ALF, Kowalski LP, de Castro JG et al (2025) Preoperative neoadjuvant chemotherapy or immunotherapy in head and neck cancer: A systematic review and meta-analysis of surgical risk and pathologic response. Crit Rev Oncol Hematol 212:104742","journal-title":"Crit Rev Oncol Hematol"},{"key":"1587_CR12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","volume":"6","author":"JD Schoenfeld","year":"2020","unstructured":"Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS et al (2020) Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol 6:1563\u20131570","journal-title":"JAMA Oncol"},{"key":"1587_CR13","doi-asserted-by":"publisher","first-page":"100426","DOI":"10.1016\/j.xcrm.2021.100426","volume":"2","author":"HM Knochelmann","year":"2021","unstructured":"Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM et al (2021) Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med 2:100426","journal-title":"Cell Rep Med"},{"key":"1587_CR14","doi-asserted-by":"publisher","first-page":"11234","DOI":"10.1002\/cam4.5815","volume":"12","author":"U Nindra","year":"2023","unstructured":"Nindra U, Hurwitz J, Forstner D, Chin V, Gallagher R, Liu J (2023) A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma. Cancer Med 12:11234\u201311247","journal-title":"Cancer Med"},{"key":"1587_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102337","author":"A Zotta","year":"2024","unstructured":"Zotta A, Marciano ML, Sabbatino F, Ottaiano A, Cascella M, Pontone M et al (2024) Neoadjuvant immunotherapy in head and neck cancers: a paradigm shift in treatment approach. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12102337","journal-title":"Biomedicines"},{"key":"1587_CR16","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1245\/s10434-024-16587-w","volume":"32","author":"W Widjaja","year":"2025","unstructured":"Widjaja W, Ng I, Shannon N, Iyer NG (2025) Neoadjuvant immunotherapy in resectable HNSCC: an updated systematic review and meta-analysis. Ann Surg Oncol 32:2713\u20132724","journal-title":"Ann Surg Oncol"},{"key":"1587_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14196883","volume":"14","author":"L Siafa","year":"2025","unstructured":"Siafa L, Ali A, Kerr P, Pathak A, Viallet N, Lane C et al (2025) Neoadjuvant treatment approaches to oral cancer. J Clin Med 14:6883","journal-title":"J Clin Med"},{"key":"1587_CR18","first-page":"105","volume":"34","author":"LI Jinsong","year":"2026","unstructured":"Jinsong LI, Guiqing L, Longjiang LI, Chenping Z, Zhengjun S, Jie Z et al (2026) Expert consensus on neoadjuvant PD-1 inhibitors for locally advanced oral squamous cell carcinoma (2026 edition). J Prev Treat Stomatol Dis 34:105\u201318","journal-title":"J Prev Treat Stomatol Dis"},{"key":"1587_CR19","doi-asserted-by":"publisher","first-page":"1627442","DOI":"10.3389\/fimmu.2025.1627442","volume":"16","author":"D Wang","year":"2025","unstructured":"Wang D, Zeng F, Zhang S, Hu W, Wang Y, Ouyang D et al (2025) Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study. Front Immunol 16:1627442","journal-title":"Front Immunol"}],"container-title":["Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-026-01587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10006-026-01587-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-026-01587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:04:36Z","timestamp":1782457476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10006-026-01587-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1587"],"URL":"https:\/\/doi.org\/10.1007\/s10006-026-01587-9","relation":{},"ISSN":["1865-1569"],"issn-type":[{"value":"1865-1569","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"102"}}